Compare YieldMax TSLA Option Income Strategy ETF (TSLY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax TSLA Option Income Strategy ETF vs Zimmer Biomet Holdings Inc — how do they compare? YieldMax TSLA Option Income Strategy ETF trades at $21.51, while Zimmer Biomet Holdings Inc trades at $95.95 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while YieldMax TSLA Option Income Strategy ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| TSLY | ZBH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $48.25 | $107.71 |
52-Week Low | $20.49 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSLY trades at $21.51, down 1.01% today, with a bearish technical signal from moving averages and mixed oscillators. The ETF generates high income through weekly distributions, but faces capped upside due to its covered call strategy on Tesla. Recent news highlights concerns over missed Tesla rallies and reduced upside capture, while distributions remain consistent, averaging around $0.28 per share recently.
Outlook is cautious due to structural limitations in capturing Tesla's gains, presenting income opportunity but significant growth risk. Investors face volatility from Tesla's performance and potential return of capital in distributions, warranting careful assessment of income versus capital appreciation goals.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
